Karyopharm Therapeutics Inc (KPTI) Looks Ready for Growth Despite 54.91% Change This Year

Karyopharm Therapeutics Inc (NASDAQ: KPTI) is 54.91% higher on its value in year-to-date trading and has touched a low of $0.62 and a high of $4.87 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The KPTI stock was last observed hovering at around $1.51 in the last trading session, with the day’s loss setting it -0.17%.

Currently trading at $1.34, the stock is 39.20% and 53.04% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.1 million and changing -11.26% at the moment leaves the stock -8.47% off its SMA200. KPTI registered -59.15% loss for a year compared to 6-month loss of -19.76%. The firm has a 50-day simple moving average (SMA 50) of $0.84 and a 200-day simple moving average (SMA200) of -$1.06.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


Sponsored

The stock witnessed a 63.00% gain in the last 1 month and extending the period to 3 months gives it a 78.67%, and is 28.85% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 32.86% over the week and 17.62% over the month.

Profit margin for the company is -95.82%. Distance from 52-week low is 117.04% and -72.48% from its 52-week high. The company has generated returns on investments over the last 12 months (-188.94%).

Karyopharm Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.31 with sales reaching $35.35M over the same period.The EPS is expected to grow by 40.81% this year, but quarterly earnings will post -6.00% year-over-year. Quarterly sales are estimated to grow 5.30% in year-over-year returns.

Karyopharm Therapeutics Inc (KPTI) Top Institutional Holders

164 institutions hold shares in Karyopharm Therapeutics Inc (KPTI), with institutional investors hold 75.10% of the company’s shares. The shares outstanding are 113.21M, and float is at 106.33M with Short Float at 17.77%. Institutions hold 71.39% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 11.54 million shares valued at $20.65 million. The investor’s holdings represent 10.09% of the KPTI Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 8.68 million shares valued at $15.54 million to account for 7.59% of the shares outstanding. The other top investors are Avidity Partners Management, LP which holds 8.37 million shares representing 7.32% and valued at over $14.98 million, while Palo Alto Investors Lp holds 4.96% of the shares totaling 5.68 million with a market value of $10.16 million.

Karyopharm Therapeutics Inc (KPTI) Insider Activity

A total of 8 insider transactions have happened at Karyopharm Therapeutics Inc (KPTI) in the last six months, with sales accounting for 7 and purchases happening 1 times. The most recent transaction is an insider sale by Mason Michael ,the company’sEVP, CFO & Treasurer. SEC filings show that Mason Michael sold 4,205 shares of the company’s common stock on Feb 06 at a price of $1.59 per share for a total of $6671.0. Following the sale, the insider now owns 0.25 million shares.

Karyopharm Therapeutics Inc disclosed in a document filed with the SEC on Feb 06 that Paulson Richard A. (President and CEO) sold a total of 4,012 shares of the company’s common stock. The trade occurred on Feb 06 and was made at $1.59 per share for $6365.0. Following the transaction, the insider now directly holds 0.82 million shares of the KPTI stock.

Still, SEC filings show that on Jan 04, Paulson Richard A. (President and CEO) disposed off 4,114 shares at an average price of $0.82 for $3373.0. The insider now directly holds 783,465 shares of Karyopharm Therapeutics Inc (KPTI).

Karyopharm Therapeutics Inc (KPTI): Who are the competitors?

The company’s main competitors (and peers) include Bristol Myers Squibb Co. (BMY) that is trading -31.93% down over the past 12 months. Abbott Laboratories (ABT) that is 3.03% higher over the same period.